BioCentury
ARTICLE | Clinical News

Tesaro informs doctors of hypersensitivity risks with Varubi

January 19, 2018 5:15 AM UTC

Tesaro Inc. (NASDAQ:TSRO) issued a Dear Health Care Provider letter for Varubi rolapitant IV (SCH 619734) saying that anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions have been reported in the postmarketing setting, some of which required hospitalization. The company said the reactions occurred during or shortly after infusion of Varubi.

The letter advises healthcare professionals to be vigilant for signs of hypersensitivity or anaphylaxis in patients receiving Varubi and to consult with patients to determine if they might be hypersensitive to any component of the product, including soybean oil. Patients with known allergies to legumes or other related allergens should be monitored closely as cross reactions are possible...